Ipamorelin + Epitalon Stack: Complete Protocol, Dosing, and Evidence Review

Can You Stack Ipamorelin With Epitalon?

Yes, the two peptides can be combined. Their mechanisms do not overlap in any way that would cause direct pharmacological antagonism. Ipamorelin acts on the growth hormone secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus to produce discrete GH pulses, while Epitalon is believed to activate telomerase and regulate melatonin synthesis through the pineal gland. Because each peptide operates on a distinct biological target, combining them is mechanistically coherent.

Practitioners who use both together typically do so to address two separate aging-related processes simultaneously: declining GH axis activity and progressive telomere shortening. Whether the clinical effect of the combination exceeds each peptide used alone has not been tested in a controlled trial.

Why the Mechanisms Are Compatible

Ipamorelin selectively binds GHSR-1a without meaningfully raising cortisol or prolactin at standard doses, a property confirmed in comparative GHRP studies published in peer-reviewed endocrinology literature. Growth hormone-releasing peptides and the growth hormone secretagogue receptor are reviewed in detail in Kojima et al., Nature 1999.

Epitalon (Ala-Glu-Asp-Gly) was derived from epithalamin, a pineal extract studied by Vladimir Khavinson's group in Russia beginning in the 1970s. The peptide does not bind GHSR-1a. Its proposed mechanism involves upregulation of telomerase reverse transcriptase (TERT) expression in somatic cells.

What the Evidence Actually Supports

The honest summary: Ipamorelin has better-characterized human pharmacokinetics than Epitalon. A 1998 study by Raun et al. In European Journal of Endocrinology showed Ipamorelin produced selective, dose-dependent GH release in rats with a profile superior to GHRP-6 and GHRP-2 in terms of cortisol and prolactin sparing. Raun K et al., 1998.

Epitalon's human data comes primarily from Khavinson's group. A 2003 paper in Neuroendocrinology Letters reported that Epitalon peptide normalized melatonin rhythm and reduced markers of oxidative stress in elderly patients across a small cohort. The sample sizes were small and the trials were not blinded to modern standards. Khavinson VKh et al., 2003.

No trial has enrolled patients to receive both peptides simultaneously. Every protocol recommendation in this article reflects expert synthesis, not Level I evidence.

How Ipamorelin Works: Mechanism and GH Axis Effects

Ipamorelin is a pentapeptide (Aib-His-D-2Nal-D-Phe-Lys-NH2) that selectively agonizes GHSR-1a. Unlike GHRP-6, it does not substantially increase appetite through NPY pathways, and unlike GHRP-2, it does not produce clinically meaningful cortisol or prolactin spikes at doses below 300 mcg.

The downstream effect of GHSR-1a activation is pulsatile secretion of growth hormone from anterior pituitary somatotrophs. GH then stimulates hepatic production of IGF-1, which mediates most of GH's anabolic and metabolic actions.

GH Pulse Characteristics

A subcutaneous injection of 100 to 300 mcg Ipamorelin triggers a GH pulse peaking roughly 15 to 30 minutes post-injection, returning toward baseline within 2 to 3 hours. This mirrors the physiological nocturnal GH pulse pattern more closely than continuous GH infusion. Physiological GH pulsatility and its metabolic relevance are described in Ho KY et al., J Clin Invest 1988.

Stacking Ipamorelin with a growth hormone-releasing hormone (GHRH) analog such as CJC-1295 amplifies the GH pulse through a separate receptor (GHRH-R), but that combination is outside the scope of this article.

IGF-1 as a Monitoring Biomarker

Because IGF-1 integrates GH secretion over 24 hours, serum IGF-1 measured at 8 weeks reflects the net effect of an Ipamorelin course better than single-point GH measurements. A target of IGF-1 in the upper-normal range for age (roughly 150 to 300 ng/mL in adults aged 30 to 60) is reasonable. Supraphysiological IGF-1 levels above 350 ng/mL may increase insulin resistance, so monitoring matters. IGF-1 reference ranges and metabolic implications are summarized in Bidlingmaier M et al., Horm Res Paediatr 2014.

How Epitalon Works: Telomerase, Melatonin, and Aging

Epitalon is a tetrapeptide analog of epithalamin, the natural peptide bioregulator produced in the pineal gland. Its two most studied effects are telomerase activation in somatic cells and normalization of melatonin synthesis in aging pinealocytes.

Telomerase Activation

Telomeres shorten with each cell division. When telomere length falls below a critical threshold, the cell enters replicative senescence. Telomerase, encoded by the TERT gene, can elongate telomeres, but its expression is suppressed in most adult somatic cells.

A 2003 study by Khavinson et al. Published in Bulletin of Experimental Biology and Medicine reported that Epitalon increased TERT expression and telomere length in human fetal fibroblasts in vitro. Khavinson VKh et al., Bull Exp Biol Med 2003. The in-vitro finding is biologically plausible; whether the same effect occurs at the same magnitude in vivo in adult humans remains unproven.

Telomere biology and aging are a well-supported research area independent of Epitalon. The Nobel Prize in Physiology or Medicine 2009 was awarded to Blackburn, Greider, and Szostak for telomerase discovery. Blackburn EH et al., reviewed in Nobel Assembly summary, 2009.

Melatonin and Circadian Regulation

The pineal gland's melatonin output declines progressively after age 40. Lower melatonin correlates with disrupted sleep architecture, reduced immune surveillance, and increased oxidative stress. Khavinson's 2003 Neuroendocrinology Letters trial (N=14 elderly subjects) reported that a 10-day Epitalon course increased urinary 6-sulfatoxymelatonin, a melatonin metabolite, by approximately 18% from baseline. The study was open-label and the sample was small, but it provides the only human biomarker data currently indexed in PubMed. Khavinson VKh et al., 2003.

The Complete Ipamorelin + Epitalon Stack Protocol

The protocol below synthesizes mechanism-based reasoning, published pharmacokinetic data for each peptide individually, and practitioner-reported outcomes from longevity-focused clinics. It has not been validated in a randomized trial. Treat it as an informed starting point, not a definitive prescription.

Phase 1: Preparation and Baseline Labs

Before starting either peptide, obtain:

• Fasting IGF-1
• Fasting insulin and glucose (HOMA-IR calculation)
• CBC with differential
• Comprehensive metabolic panel
• Melatonin (serum, AM collection) or 6-sulfatoxymelatonin (first-morning urine)
• Testosterone (total and free) and SHBG if clinically indicated

Baseline labs serve two purposes: they identify contraindications (active malignancy is a relative contraindication to telomerase activation; poorly controlled diabetes contraindicates further GH axis stimulation) and they provide a comparison point for benefit assessment at 8 weeks.

Phase 2: Ipamorelin Dosing Schedule

Dose: 100 to 200 mcg per injection for most adults. Experienced users or those with documented IGF-1 deficiency may use 300 mcg under physician supervision.

Frequency: Once daily before bed to align with physiological nocturnal GH surge, or twice daily (pre-bed and pre-workout) for those pursuing body composition change.

Administration: Subcutaneous injection into the abdomen or flank. Rotate sites. Reconstitute lyophilized powder with bacteriostatic water; store reconstituted vials at 2 to 8°C and use within 30 days.

Cycle length: 8 to 12 weeks on, followed by 4 to 6 weeks off. Continuous use beyond 12 weeks may blunt receptor sensitivity through GHSR-1a downregulation, though this has been studied in animal models rather than controlled human trials. GHSR desensitization mechanisms are reviewed in Camiña JP, Front Neuroendocrinol 2006.

Timing relative to food: Administer Ipamorelin in a fasted state, at least 2 hours after the last meal. Elevated glucose and insulin blunt GH pulse amplitude through somatostatin release.

Phase 3: Epitalon Dosing Schedule

Dose: 5 to 10 mg per day. Most published human case series used 5 mg/day. The 10 mg/day dose appears in some practitioner protocols for older patients (60+) but lacks comparative trial data.

Administration: Subcutaneous injection once daily, preferably in the evening given its melatonin-related mechanism. Some clinics use intravenous administration over a short infusion, but subcutaneous is more practical in an outpatient setting.

Cycle length: 10 to 20 days per course, repeated 2 to 4 times per year. Khavinson's published protocols used a 10-day course twice annually. The rationale for intermittent rather than continuous dosing is partly to minimize any theoretical risk of inappropriate telomerase activation in cells with oncogenic mutations, and partly to mimic the episodic biology of pineal peptide release.

Stagger vs. Simultaneous injection: Both peptides can be injected at the same time of day (e.g., pre-bed) in separate subcutaneous sites. There is no pharmacokinetic interaction data suggesting simultaneous injection causes problems, but separating injection sites by at least 2 inches is standard subcutaneous practice to reduce local tissue load.

Phase 4: Monitoring On-Cycle

At 4 weeks: Check fasting glucose. Ipamorelin can cause transient insulin resistance by opposing insulin's suppression of hepatic gluconeogenesis. Any glucose above 110 mg/dL fasting warrants dose review.

At 8 weeks: Repeat IGF-1. A 20 to 40% rise from baseline is the commonly cited target range in practitioner literature. IGF-1 above 350 ng/mL in adults is a signal to reduce Ipamorelin dose.

At end of Epitalon course (day 10 to 20): Patients with baseline sleep disruption often report improved sleep latency and dream vividness within the first week. This is consistent with the melatonin-normalization mechanism and is a useful qualitative marker, not a validated endpoint.

Phase 5: Off-Cycle and Cycling Frequency

The off-cycle period for Ipamorelin (4 to 6 weeks) allows GHSR-1a sensitivity to recover. During the off-cycle, endogenous GH pulsatility is not suppressed the way it would be by exogenous recombinant GH, because Ipamorelin is a secretagogue rather than a replacement.

Epitalon courses are brief enough (10 to 20 days) that they can be inserted during either the on- or off-cycle of Ipamorelin. Many practitioners schedule an Epitalon course at the start of each Ipamorelin cycle. Others run Epitalon twice yearly independently of the Ipamorelin schedule.

Side Effects and Safety Profile

Ipamorelin Side Effects

Ipamorelin's side-effect profile is cleaner than older GHRPs specifically because of GHSR-1a selectivity. At doses below 300 mcg:

• Water retention in the first 2 weeks, typically resolving without intervention
• Mild flushing or tingling at the injection site, usually lasting under 30 minutes
• Transient headache in roughly 10 to 15% of first-time users, based on aggregated clinical observation rather than a controlled trial
• Fatigue or drowsiness if injected during the day (this is actually favorable when dosed pre-bed)

Cortisol and prolactin elevation, common complaints with GHRP-6 and GHRP-2, are not meaningfully observed with Ipamorelin at standard doses. Raun K et al., 1998, confirmed this in a direct comparative study.

Theoretical risk of accelerating pre-existing neoplastic growth via IGF-1 upregulation exists by mechanism. This risk is shared by all GH secretagogues. Active malignancy is a contraindication.

Epitalon Side Effects

Epitalon's published safety record in Khavinson's studies shows a favorable profile. Reported adverse events in human studies were limited to transient injection-site redness. No hepatotoxicity, no endocrine disruption outside the intended melatonin pathway, and no serious adverse events were reported in published cohorts.

The theoretical concern with telomerase activation is oncogenesis: in cancer cells, telomerase is already reactivated, and any additional telomerase stimulation could theoretically support tumor growth. This concern is extrapolated from oncology biology rather than observed in Epitalon studies, but it is sufficient reason to screen for active or recent malignancy before prescribing.

Drug Interactions

Neither peptide has well-characterized drug-interaction data from clinical trials. Pharmacokinetic interactions are unlikely given the peptides' small size, rapid proteolytic degradation, and distinct receptor targets. The combination of Ipamorelin with exogenous insulin or insulin sensitizers (metformin, GLP-1 receptor agonists) warrants closer glucose monitoring, because GH's counter-regulatory effect on insulin action may blunt glycemic control.

Regulatory Status and Prescribing Context

Neither Ipamorelin nor Epitalon holds FDA approval for any therapeutic indication in the United States. Ipamorelin has been studied in phase II trials for postoperative ileus (NCT00609219) but was not submitted for approval in that indication. ClinicalTrials.gov NCT00609219.

In January 2025, the FDA finalized guidance restricting certain bulk compounding of peptides including some GHRP compounds. Clinicians and patients should verify current regulatory status with a licensed compounding pharmacy and a physician familiar with peptide prescribing before initiating any protocol. FDA compounding guidance updates are maintained at fda.gov/drugs/human-drug-compounding.

Epitalon is not listed on any FDA drug application. It is sold as a research chemical in the United States and is available as a licensed pharmaceutical in some European countries under different regulatory frameworks.

Who Is This Stack For? Patient Selection Criteria

The Ipamorelin plus Epitalon combination is used most consistently in three patient profiles:

Older adults focused on longevity markers. Adults aged 45 and above with documented IGF-1 in the lower quartile for age, combined with any of: poor sleep quality, elevated fasting glucose, low lean mass, or elevated inflammatory markers. Both peptides address mechanisms that deteriorate with normal aging.

Recovery-focused younger adults. Adults aged 30 to 45 recovering from significant physical stress (overtraining, surgery, prolonged caloric deficit) who want GH axis support without exogenous recombinant GH. Epitalon is added to support sleep quality during recovery.

Patients who have already completed a GHRH/GHRP stack and want longevity-specific add-on. For this group, Epitalon is the primary new element; Ipamorelin is used at 100 mcg once nightly rather than a higher twice-daily dose.

The stack is not appropriate for: pregnant or breastfeeding women, anyone with active malignancy or malignancy within the prior 5 years, adults with acromegalic features, anyone with uncontrolled type 2 diabetes (fasting glucose consistently above 180 mg/dL), or patients under 18 years of age.

Practical Reconstitution and Storage Guide

Ipamorelin Reconstitution

Ipamorelin is sold as a lyophilized powder, typically in 2 mg or 5 mg vials. Reconstitute with bacteriostatic water (0.9% benzyl alcohol in sterile water for injection). Add the water slowly down the side of the vial; never shake. Swirl gently until clear.

For a 5 mg vial reconstituted with 2.5 mL bacteriostatic water, the concentration is 2 mg/mL (2,000 mcg/mL). A 200 mcg dose requires 0.1 mL (10 units on a U-100 insulin syringe).

Store reconstituted vials at 2 to 8°C. Discard after 30 days or if the solution becomes cloudy.

Epitalon Reconstitution

Epitalon is also lyophilized. Common vial sizes are 10 mg. Reconstitute with bacteriostatic water. For a 10 mg vial with 2 mL bacteriostatic water, concentration is 5 mg/mL. A 5 mg/day dose requires 1 mL.

Epitalon is stable for 28 days after reconstitution at 2 to 8°C. Light degrades peptide bonds; keep vials in amber glass or wrapped in foil.

Summary of Evidence Gaps

The most honest statement about this stack is also the most clinically useful: neither peptide has been evaluated in a phase III randomized controlled trial at any dose or indication as of mid-2025, and no trial has studied the combination. The evidence supporting each peptide comes from:

• Animal pharmacology (Raun et al. For Ipamorelin; multiple Khavinson publications for Epitalon)
• Small, often open-label human studies (Khavinson's Epitalon melatonin data, N=14)
• Phase II human trials that measured GH pharmacodynamics but did not report clinical outcomes (Ipamorelin)
• Practitioner-reported outcomes from longevity clinics, which are subject to selection bias and placebo effects

The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency in adults states: "GH secretagogues are not recommended as a substitute for established GH replacement therapy in patients with confirmed adult GH deficiency." Molitch ME et al., J Clin Endocrinol Metab 2019. That guideline does not address Ipamorelin by name, but the class-level caution applies.

Physicians and patients using this stack should document baseline and follow-up labs, report adverse events through MedWatch, and view the protocol as investigational.